Voyageur Pharmaceuticals Ltd.
VM.V
TSX
| 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -8.24% | 94.18% | 237.10% | -28.71% | 115.66% |
| Depreciation & Amortization | 0.00% | -33.33% | -33.33% | -33.33% | -33.33% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -5.23% | 93.50% | 241.15% | -28.71% | 115.46% |
| Operating Income | 8.24% | -93.37% | -237.66% | 28.71% | -115.46% |
| Income Before Tax | 19.46% | -86.11% | -262.78% | 6.11% | -133.37% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 19.46% | -86.11% | -262.78% | 6.11% | -133.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 19.46% | -86.11% | -262.78% | 6.11% | -133.37% |
| EBIT | 8.24% | -93.37% | -237.66% | 28.71% | -115.46% |
| EBITDA | 8.24% | -93.50% | -238.02% | 28.71% | -115.66% |
| EPS Basic | 29.73% | -45.83% | -200.00% | 20.00% | -105.56% |
| Normalized Basic EPS | 30.43% | -46.67% | -200.00% | 21.05% | -91.67% |
| EPS Diluted | 29.73% | -45.83% | -200.00% | 20.00% | -105.56% |
| Normalized Diluted EPS | 30.43% | -46.67% | -200.00% | 21.05% | -91.67% |
| Average Basic Shares Outstanding | 14.83% | 27.96% | 20.08% | 16.05% | 17.16% |
| Average Diluted Shares Outstanding | 14.83% | 27.96% | 20.08% | 16.05% | 17.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |